Sign in →

Test ID MUR Lysozyme (Muramidase), Plasma

Useful For

Confirming marked increases in the granulocyte or monocyte pools as in granulocytic or monocytic leukemias, myeloproliferative disorders, and malignant histiocytosis

 

Following the course of therapy in cases of chronic granulocytic or chronic monocytic leukemias

Method Name

Turbidimetric

Reporting Name

Lysozyme (Muramidase), P

Specimen Type

Plasma EDTA

Collection Container/Tube: Lavender top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL

Forms: If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

Hematopathology/Cytogenetics Test Request Form (T726) (http://www.mayomedicallaboratories.com/it-mmfiles/hematopathology-request-form.pdf)

Benign Hematology Test Request Form (T755) (http://www.mayomedicallaboratories.com/it-mmfiles/benign-hematology-test-request-form.pdf)

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time
Plasma EDTA Frozen 30 days

Clinical Information

Lysozyme is a bacteriolytic enzyme that is found in some hematopoietic cells. It is primarily present in granulocytes, monocytes, and histiocytes. The enzyme is present in only minute amounts in lymphocytes; and is not present in myeloblasts, eosinophils, and basophils.

 

Lysozyme in the plasma comes chiefly from the degradation of granulocytes and monocytes and its concentration reflects the turnover of these cells. Increases are seen in benign (eg, infection, inflammation) and malignant processes(eg, some leukemias). Plasma lysozyme is elevated in patients with acute or chronic granulocytic or monocytic leukemias and falls with successful treatment. Conversely, patients with lymphocytic leukemia may have depressed plasma lysozyme levels.

 

Patients with renal disorders (including rejection of transplanted kidneys) or Crohn’s disease (regional enteritis) also tend to have elevated levels of plasma lysozyme.

Reference Values

≥12 months: 2.7-9.4 mcg/mL

Reference values have not been established for patients who are <12 months of age.

Cautions

Increased levels may be seen in nonmalignant disorders including infections, Crohn’s disease, kidney transplant rejection, and other renal disorders.

Day(s) Performed

Monday through Friday

Report Available

2 days

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

85549

NY State Approved

Yes